UNITED STATES OF AMERICA
Before the
SECURITIES AND EXCHANGE COMMISSION

SECURITIES EXCHANGE ACT OF 1934
Release No. 84693 / November 29, 2018

ADMINISTRATIVE PROCEEDING
File No. 3-18776

In the Matter of
ColorStars Group, et al.
Respondents.

ORDER MAKING FINDINGS AND
REVOKING REGISTRATION OF
SECURITIES PURSUANT TO SECTION 12(j)
OF THE SECURITIES
EXCHANGE ACT OF 1934 AS TO
INTELLECT NEUROSCIENCES, INC.

I.

The Securities and Exchange Commission (“Commission”) deems it necessary and
appropriate for the protection of investors to accept the Offer of Settlement submitted by Intellect
Neurosciences, Inc. (“Intellect Neurosciences” or “Respondent”) pursuant to Rule 240(a) of the
Rules of Practice of the Commission, 17 C.F.R. § 201.240(a), for the purpose of settlement of
these proceedings initiated against Respondent on September 17, 2018, pursuant to Section 12(j) of

II.

Solely for the purpose of these proceedings and any other proceedings brought by or on
behalf of the Commission, or to which the Commission is a party, and without admitting or
denying the findings herein, except as to the Commission’s jurisdiction over it and the subject
matter of these proceedings, which are admitted, Respondent consents to the entry of this Order
Making Findings and Revoking Registration of Securities Pursuant to Section 12(j) of the
Securities Exchange Act of 1934 as to Intellect Neurosciences, Inc. (“Order”), as set forth below.
III.

On the basis of this Order and Respondent’s Offer, the Commission finds¹ that:

1. Intellect Neurosciences (CIK No. 1337905) is a Delaware corporation located in Englewood Cliffs, New Jersey. At all times relevant to this proceeding, the securities of Intellect Neurosciences have been registered under Exchange Act Section 12(g). As of August 29, 2018, the company’s stock (symbol “ILNS”) was quoted on OTC Link (previously “Pink Sheets”) operated by OTC Markets Group Inc. (“OTC Link”), had six market makers, and was eligible for the “piggyback” exception of Exchange Act Rule 15c2-11(f)(3).

2. Intellect Neurosciences failed to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 thereunder because it has not filed any periodic reports with the Commission since March 31, 2016.

IV.

In view of the foregoing, the Commission deems it necessary and appropriate for the protection of investors to impose the sanction specified in Respondent’s Offer.

Accordingly, it is hereby ORDERED, pursuant to Section 12(j) of the Exchange Act, that registration of each class of Respondent’s securities registered pursuant to Section 12 of the Exchange Act be, and hereby is, revoked. The revocation is effective as of November 30, 2018.

For the Commission, by its Secretary, pursuant to delegated authority.

Brent J. Fields
Secretary

¹The findings herein are made pursuant to Respondent’s Offer of Settlement and are not binding on any other person or entity in this or any other proceeding.